Vermillion, Inc. (NASDAQ:VRML)

CAPS Rating: 1 out of 5


Results 1 - 12 of 12


Member Avatar zzlangerhans (99.56) Submitted: 8/9/2015 2:14:33 PM : Underperform Start Price: $2.00 VRML Score: -8.96

Vermillion is one of those mystifying companies that seems to exist mainly for the purpose of raising money through issuance of secondary offerings. One strange fact about the stock market is that a company which has no viable product and steadily loses money can continue operations indefinitely simply by selling discounted shares, as long as they can find slimy brokers to manage the offering who in turn can find enough buyers on whom to pawn the worthless equity. In the case of Vermillion, the strongest selling point would seem to be that the company is raising enough money to keep them solvent until the next secondary financing.

Despite quarterly optimistic pronouncements, Vermillion's OVA1 sales have remained statically weak for years and show no reasonable prospect of improving. The company likewise seems to have no near term prospects for new revenue-generating products. Nevertheless, they were recently able to raise 18M from a public offering at 1.96 which will pay executive salaries for another couple of years. However, every additional raise makes the market cap harder to justify and lowers the already pathetic EPS. I suspect that once Vermillion reports weak OVA1 sales yet again on August 13, the share price will resume a downward trajectory. zzporte is short 5000 shares with cost basis 2.04.


Member Avatar SmartAce (99.90) Submitted: 8/4/2015 3:30:44 PM : Underperform Start Price: $1.99 VRML Score: -9.33

“Memories of childhood were the dreams that stayed with you after you woke.”


Member Avatar allstar31 (99.83) Submitted: 7/27/2011 9:50:38 PM : Underperform Start Price: $4.00 VRML Score: +103.73

TMF Stock Spam. Garbage.


Member Avatar znose (< 20) Submitted: 5/14/2011 9:55:30 AM : Outperform Start Price: $6.08 VRML Score: -116.25

Current testing for ovarian cancer, when a mass is detected, is just slightly better than a coin flip. An ovary's fate compares to a tonsil's in the sixties. With the price of gasoline blowing past $4 a gallon and escalating "greens fees" at the country club, most gynecologic oncologists will have to start doing elective plastic surgery on the side, once Vermillion's OVA1 test becomes the new standard.


Member Avatar investorpatent (< 20) Submitted: 1/31/2011 5:23:59 PM : Outperform Start Price: $5.31 VRML Score: -134.04

One of the best buys for 2011, existing OVA1 product has double digit growth quarter on quarter. New PAD test will generate hype sometimes in the middle of the year. You get existing business and hype, best of both worlds.


Member Avatar longterm90 (< 20) Submitted: 1/12/2011 12:57:37 AM : Outperform Start Price: $8.25 VRML Score: -131.63

They have several patents on a global bases. OVAR1 for ovarian cancer, and they just received one for PAD. The stock price has been up to $34 and I am sure it will go well beyond $34 on this run.


Member Avatar 21popsontop (< 20) Submitted: 11/24/2010 5:59:04 AM : Outperform Start Price: $5.04 VRML Score: -127.29

Fremont ,CA & Diagnostic Substances could get some attention after end of year tax dip.


Member Avatar LatePlay (< 20) Submitted: 8/23/2010 9:32:40 AM : Outperform Start Price: $6.23 VRML Score: -152.36

Ovarian cancer drug maker.

Coverage initiated by Wedbush - Outperform - Target $10

52 Week Range $0.04 - $34

Short Interest Days to Cover - 7.88


Member Avatar tttchicattt (95.95) Submitted: 8/19/2010 4:50:52 AM : Outperform Start Price: $6.15 VRML Score: -150.25



Member Avatar MstrGold (29.62) Submitted: 7/16/2010 3:18:04 AM : Underperform Start Price: $11.65 VRML Score: +166.59

If I said about Bonton that their financials are horrible, then Vermillion is ten times worse.
Cash barely covers accounts payables, in addition debt of 10M and around 250M in negative earnings with market cap of 114M?
Motto - "Your health, our passion." - Sorry VRML, this is about business right now.
If I was a seer - then I don't foresee much success for this company in the future.


Member Avatar TMFStockSpam (99.99) Submitted: 6/29/2010 2:26:29 PM : Underperform Start Price: $13.85 VRML Score: +165.29

VRML, Vermillion, Inc. (Other OTC: VRML.PK)

June 18th, 2010

Last Price: $13.50
52wk Range: 0.01 - 34.00

VRML is a molecular diagnostics company based in Fremont, California.

Announced just recently the European Patent Office has issued a Decision to Grant patent number 1,493,741 entitled "Use of Biomarkers for Detecting Ovarian Cancer" to the Company.

The patent claims are directed to biomarker combinations for the diagnosis and management of ovarian cancer and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.

Check out the Year to Date chart below to see the growth spread since Mid September 2009.

About VRML

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.

Find out more about VRML at their website:


Member Avatar DarthMaul09 (29.73) Submitted: 10/21/2009 11:41:52 PM : Underperform Start Price: $16.90 VRML Score: +173.73

To add to knnryerye insight about this company:
On Oct 9 they received some cash on a warrant deal.
It sounds that they may have received some encouraging news from the FDA (Kiss of Death).
Stock price shoots up on speculation that they may have a real drug to sell to another company.
Reality kicks in and the mountain begins to look like an iceberg.
Cracks begin to form and it looks like a big piece is about to fall off.
It was probably burning all the new cash which started the melt down.
Botton line: knnryerye was right, this is a speculative bet on gravity.

Results 1 - 12 of 12

Featured Broker Partners